Filtros de búsqueda

Lista de obras de Johann S de Bono

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?

artículo científico publicado en 2008

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer ⬇️

artículo científico publicado el 24 de noviembre de 2010

A decade of clinical development of PARP inhibitors in perspective

scientific article published on 01 September 2019

A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer

artículo científico publicado en 2022

A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies.

artículo científico publicado en 2007

A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI), in patients with advanced solid tumours

artículo científico publicado en 2009

A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors

artículo científico publicado en 2012

A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors.

artículo científico publicado en 2016

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors

artículo científico publicado en 2018

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.

artículo científico

A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer

scientific article published on 16 October 2014

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer

artículo científico publicado en 2015

A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.

artículo científico publicado en 2018

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

artículo científico publicado en 2018

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

artículo científico publicado en 2017

A study of motivations and expectations of patients seen in phase 1 oncology clinics

scientific article published on 26 September 2016

A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition.

artículo científico publicado en 2010

Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

artículo científico publicado en 2017

Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer

scientific article published on 23 August 2019

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

artículo científico publicado en 2015

Agents that target androgen synthesis in castration-resistant prostate cancer

artículo científico

Alternative splicing in prostate cancer

artículo científico publicado en 2018

Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials

scientific article published on 12 December 2019

Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer.

artículo científico publicado en 2018

Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors

artículo científico publicado en 2011

Biomarkers in early clinical trials: the committed and the skeptics

scientific article published on 01 April 2008

CDCP1 overexpression drives prostate cancer progression and can be targeted in vivo

artículo científico publicado en 2020

CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions

artículo científico publicado en 2018

Cabazitaxel in Metastatic Prostate Cancer. Reply

artículo científico publicado en 2020

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

artículo científico publicado en 2019

Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study

artículo científico publicado en 2008

Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study

artículo científico publicado en 2003

Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses

artículo científico publicado en 2016

Changing Therapeutic Paradigms in Castrate-Resistant Prostate Cancer ⬇️

artículo científico publicado el 1 de diciembre de 2010

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

artículo científico publicado en 2016

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

artículo científico publicado en 2017

Circulating cell-free DNA: Translating prostate cancer genomics into clinical care

scientific article published on 16 January 2020

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients.

artículo científico publicado en 2018

Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.

artículo científico publicado en 2016

Clinical benefit of early phase clinical trial participation for advanced sarcoma patients

artículo científico publicado en 2010

Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer

artículo científico publicado en 2009

Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel

artículo científico publicado en 2017

Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial

artículo científico publicado en 2014

Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer.

artículo científico publicado en 2018

Consensus on molecular imaging and theranostics in prostate cancer

artículo científico publicado en 2018

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

artículo científico publicado en 2017

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus

artículo científico publicado en 2008

DNA Repair and Prostate Cancer: A Field Ripe for Harvest

artículo científico publicado en 2020

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer

artículo científico publicado en 2016

Development of a molecular profiling assay for circulating tumor cells (CTCs) utilizing automated multiplexed in situ hybridization for metastatic castrate-resistant prostate cancer (mCRPC).

artículo científico publicado en 2012

Differential impact of RB status on E2F1 reprogramming in human cancer

artículo científico publicado en 2017

Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer

artículo científico publicado en 2017

Drugs and the exercise test ⬇️

artículo científico publicado el 3 de octubre de 1992

Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).

artículo científico publicado en 2007

Early Oncology Clinical Trial Design in the Era of Molecular-Targeted Agents ⬇️

artículo científico publicado el 1 de agosto de 2010

Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors

artículo científico publicado en 2009

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

artículo científico

Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial

artículo científico publicado en 2014

Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies

artículo científico publicado en 2021

Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis

artículo científico publicado en 2014

Enzalutamide in European and North American men participating in the AFFIRM trial

artículo científico publicado en 2014

EpCAM and EpCAM circulating tumor cells in metastatic prostate and breast cancer patients

artículo científico publicado en 2018

Erratum to: Methods for evaluating medical tests and biomarkers

artículo científico publicado en 2017

Evolution of androgen receptor targeted therapy for advanced prostate cancer

artículo científico

Expression profiling of CD133+ and CD133- epithelial cells from human prostate.

artículo científico publicado en 2008

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial

artículo científico publicado en 2015

Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma ⬇️

artículo científico publicado el 1 de octubre de 2003

Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial

artículo científico publicado en 2012

Flexible trial design in practice – dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial

artículo científico publicado en 2011

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification

artículo científico publicado en 2017

Genetic Analysis of Circulating Tumour Cells

artículo científico publicado en 2020

HDAC inhibitors and cardiac safety

scientific article published on 01 February 2007

HER3 Is an Actionable Target in Advanced Prostate Cancer

artículo científico publicado en 2021

Histone deacetylase inhibitors: emerging anticancer therapeutic agents?

artículo científico publicado en 2005

Hypoxia and Noncoding RNAs in Taxane Resistance

artículo científico publicado en 2018

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer

scientific article published in Nature

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital

artículo científico publicado en 2008

Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art

scientific article published on 25 June 2019

Immunotherapy for lethal prostate cancer

artículo científico publicado en 2019

Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms

artículo científico publicado en 2013

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

scientific article published on 06 July 2016

Integrative Clinical Genomics of Advanced Prostate Cancer.

artículo científico publicado en 2015

Integrative clinical genomics of advanced prostate cancer

artículo científico publicado en 2015

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey

artículo científico publicado en 2016

Interview with Johann de Bono for Future Oncology. Interviewed by Francesca Lake

artículo científico publicado en 2012

Is there an antiandrogen withdrawal syndrome with enzalutamide?

artículo científico publicado en 2014

JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer

artículo científico publicado en 2021

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

artículo científico publicado en 2016

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer.

artículo científico publicado en 2016

Making sense of antisense

artículo científico publicado en 2005

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019

artículo científico publicado en 2020

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

artículo científico publicado en 2017

Management of patients with castration-resistant disease.

artículo científico

Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

artículo científico publicado en 2016

Metabolomic changes of the multi (-AGC-) kinase inhibitor AT13148 in cells, mice and patients are associated with NOS regulation

artículo científico publicado en 2020

Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics

artículo científico

Methods for Evaluating Medical Tests and Biomarkers

article by Gowri Gopalakrishna et al published February 2017 in Diagnostic and Prognostic Research

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab

artículo científico publicado en 2020

Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids.

artículo científico publicado en 2017

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors.

artículo científico publicado en 2017

New therapies for castration-resistant prostate cancer: efficacy and safety

scientific article published on 04 May 2011

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting

artículo científico publicado en 2011

Olaparib for Metastatic Castration-Resistant Prostate Cancer

artículo científico publicado en 2020

Olaparib for Metastatic Castration-Resistant Prostate Cancer. Reply

artículo científico publicado en 2020

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

artículo científico publicado en 2007

Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities

artículo científico publicado en 2012

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

artículo científico publicado en 2020

PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients

artículo científico publicado en 2015

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

artículo científico publicado en 2014

Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress

artículo científico publicado en 2011

Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer

artículo científico publicado en 2016

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

artículo científico publicado en 2018

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

artículo científico publicado en 2019

Perceptions and referral trends into phase I oncology trials: results of a clinical survey

artículo científico publicado en 2011

Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer

artículo científico publicado en 2019

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

artículo científico publicado en 2007

Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.

artículo científico publicado en 2010

Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies

artículo científico publicado en 2007

Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer

artículo científico publicado en 2007

Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.

artículo científico publicado en 2018

Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors.

artículo científico publicado en 2009

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors

artículo científico publicado en 2014

Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?

artículo científico publicado en 2011

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

artículo científico publicado en 2017

Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer.

artículo científico publicado en 2006

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

artículo científico publicado en 2013

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.

artículo científico publicado en 2017

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

artículo científico publicado en 2016

Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based th

artículo científico publicado en 2015

Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer

artículo científico publicado en 2017

Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

artículo científico publicado en 2018

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic ⬇️

artículo científico publicado el 4 de enero de 2011

Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.

artículo científico publicado en 2014

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial ⬇️

artículo científico publicado el 2 de octubre de 2010

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer ⬇️

artículo científico publicado el 26 de enero de 2011

Prognostic factors for survival in the phase III TROPIC trial

Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy

artículo científico publicado en 2013

Prospective validation of a prognostic score to improve patient selection for oncology phase I trials

artículo científico publicado en 2009

Prostate cancer: evolution or revolution?

artículo científico publicado en 2011

Prostate carcinogenesis: inflammatory storms

artículo científico publicado en 2020

Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy

artículo científico publicado en 2013

Publisher Correction: Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer

artículo científico publicado en 2018

Publisher Correction: The long tail of oncogenic drivers in prostate cancer

scientific article published on 01 July 2019

Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study

artículo científico publicado en 2020

RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease

publication published on 20 April 2021

RB1 Heterogeneity in Advanced Metastatic Castration Resistant Prostate Cancer

scientific article published on 26 September 2018

RETRACTED: Horizon scanning for novel therapeutics for the treatment of prostate cancer ⬇️

artículo científico publicado el 24 de septiembre de 2010

RNAi screen reveals synthetic lethality between cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses

artículo científico publicado en 2017

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

artículo científico publicado en 2017

Rationale for Modernising Imaging in Advanced Prostate Cancer.

artículo científico publicado en 2016

Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer

scientific article published on 01 August 2019

Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olap

artículo científico publicado en 2020

Reappraisal of glucocorticoids in castrate-resistant prostate cancer

artículo científico publicado en 2014

Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer

artículo científico publicado en 2018

Reovirus activates human dendritic cells to promote innate antitumor immunity

artículo científico publicado en 2008

Reply from authors re: Camillo Porta, Sergio Bracarda, Romano Danesi. Steroids in prostate cancer: the jury is still out... and even more confused. Eur Urol 2015;67:680-1: Corticosteroids in prostate cancer: known benefits versus potential risks

artículo científico publicado en 2014

Reply to M. Horiguchi et al.

artículo científico publicado en 2018

Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistan

artículo científico publicado en 2016

Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant

artículo científico publicado en 2018

SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition

artículo científico publicado en 2018

SPOP mutation leads to genomic instability in prostate cancer.

artículo científico publicado en 2015

SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity

artículo científico publicado en 2018

Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin

artículo científico publicado en 2014

Scanning Electron Microscopy of Circulating Tumor Cells and Tumor-Derived Extracellular Vesicles

artículo científico publicado en 2018

Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.

artículo científico publicado en 2016

Second-generation antiandrogens in nonmetastatic CRPC

artículo científico publicado en 2018

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents

artículo científico

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

article by Louise J Barber et al published 25 January 2013 in Journal of Pathology

Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets.

artículo científico publicado en 2018

Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial

artículo científico publicado en 2016

Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis

artículo científico publicado en 2018

Study protocol for a randomised controlled trial of enhanced informed consent compared to standard informed consent to improve patient understanding of early phase oncology clinical trials (CONSENT)

artículo científico publicado en 2021

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

artículo científico publicado en 2014

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

scientific article published on 20 September 2020

Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?

scientific article published on 06 April 2020

Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre

scientific article published on 15 October 2018

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine

artículo científico publicado en 2008

Targeting IGF-1R: throwing out the baby with the bathwater? ⬇️

artículo científico publicado el 4 de enero de 2011

Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies ⬇️

artículo científico publicado el 31 de agosto de 2010

Targeting defective DNA repair in prostate cancer

scientific article published on 15 July 2020

Targeting polo-like kinase: learning too little too late?

artículo científico publicado en 2008

Targeting the p300/CBP Axis in Lethal Prostate Cancer

artículo científico publicado en 2021

The 'Pushmi-Pullyu' of DNA REPAIR: Clinical Synthetic Lethality

artículo científico publicado en 2016

The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.

artículo científico publicado en 2016

The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.

artículo científico publicado en 2012

The landscape of RNA polymerase II associated chromatin interactions in prostate cancer

scientific article published on 28 April 2020

The long tail of oncogenic drivers in prostate cancer.

artículo científico publicado en 2018

The molecular underpinnings of prostate cancer: impacts on management and pathology practice

artículo científico publicado en 2016

The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials.

artículo científico publicado en 2018

Toward a better dialogue between neuro-oncologists and phase I investigators.

artículo científico publicado en 2012

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)

artículo científico publicado en 2018

Translating cancer research into targeted therapeutics ⬇️

artículo científico publicado el 30 de septiembre de 2010

Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise

artículo científico publicado en 2017

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

scientific article published on 12 March 2020

Update on tubulin-binding agents.

artículo científico publicado en 2006

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda